Literature DB >> 10512407

Bovine colostrum ameliorates diarrhea in infection with diarrheagenic Escherichia coli, shiga toxin-producing E. Coli, and E. coli expressing intimin and hemolysin.

H I Huppertz1, S Rutkowski, D H Busch, R Eisebit, R Lissner, H Karch.   

Abstract

BACKGROUND: Diarrheagenic Escherichia coli may cause serious extraintestinal complications, but there is no specific treatment.
METHODS: Patients with diarrhea caused by diarrheagenic E. coli, specifically Shiga toxin-producing E. coli and E. coli-expressing intimin and enterohemorrhagic E. coli-hemolysin were treated by administration of pooled bovine colostrum, rich in antibodies to Shiga toxin and enterohemorrhagic E. coli-hemolysin, in a placebo-controlled, double-blind study. Symptom resolution and fecal excretion of infecting strains were assessed.
RESULTS: No side effects were attributable to colostrum. Stool frequencies in the group treated with bovine colostrum were significantly reduced compared with those in the placebo group. No effect of therapy on the carriage of the pathogens or on complications of the infection could be demonstrated.
CONCLUSIONS: Bovine colostrum is well tolerated and diminishes frequency of loose stools in children with E. coli-associated diarrhea. A prospective study should be conducted among a larger number of children with Shiga toxin-producing E. coli identified early in illness, to determine the effectiveness of colostrum therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10512407     DOI: 10.1097/00005176-199910000-00015

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  19 in total

Review 1.  Bovine colostrum in pediatric respiratory diseases: a systematic review.

Authors:  P Ramesh Menon; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2010-01       Impact factor: 1.967

2.  Bovine colostrum contains immunoglobulin G antibodies against intimin, EspA, and EspB and inhibits hemolytic activity mediated by the type three secretion system of attaching and effacing Escherichia coli.

Authors:  Daniel A Vilte; Mariano Larzábal; Angel A Cataldi; Elsa C Mercado
Journal:  Clin Vaccine Immunol       Date:  2008-06-18

Review 3.  Is There a Role for the Enteral Administration of Serum-Derived Immunoglobulins in Human Gastrointestinal Disease and Pediatric Critical Care Nutrition?

Authors:  Melissa Van Arsdall; Ikram Haque; Yuying Liu; J Marc Rhoads
Journal:  Adv Nutr       Date:  2016-05-16       Impact factor: 8.701

4.  Role of colostrum in gastrointestinal infections.

Authors:  Pawan Rawal; Vineet Gupta; B R Thapa
Journal:  Indian J Pediatr       Date:  2008-09       Impact factor: 1.967

5.  Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers.

Authors:  Wlodzimierz Otto; Boguslaw Najnigier; Teodor Stelmasiak; Roy M Robins-Browne
Journal:  Scand J Gastroenterol       Date:  2011-07       Impact factor: 2.423

6.  Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS).

Authors:  Paul N Goldwater; Karl A Bettelheim
Journal:  BMC Med       Date:  2012-02-02       Impact factor: 8.775

Review 7.  Perspectives on immunoglobulins in colostrum and milk.

Authors:  Walter L Hurley; Peter K Theil
Journal:  Nutrients       Date:  2011-04-14       Impact factor: 5.717

Review 8.  Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype.

Authors:  Elias A Rahal; Sukayna M Fadlallah; Farah J Nassar; Natalie Kazzi; Ghassan M Matar
Journal:  Front Cell Infect Microbiol       Date:  2015-03-18       Impact factor: 5.293

Review 9.  Role of Recent Therapeutic Applications and the Infection Strategies of Shiga Toxin-Producing Escherichia coli.

Authors:  Su-Bin Hwang; Ramachandran Chelliah; Ji Eun Kang; Momna Rubab; Eric Banan-MwineDaliri; Fazle Elahi; Deog-Hwan Oh
Journal:  Front Cell Infect Microbiol       Date:  2021-06-29       Impact factor: 5.293

10.  Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome.

Authors:  Aamer Imdad; Samuel P Mackoff; David M Urciuoli; Tamkeenat Syed; Emily E Tanner-Smith; Dongmei Huang; Oscar G Gomez-Duarte
Journal:  Cochrane Database Syst Rev       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.